BIOMAT Database Logo BIOMAT Database Logo

Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer. 2000

M Hillenbrand, and M Bastian, and M Steiner, and C Zingler, and M Müller, and J M Wolff, and H Seiter, and P Schuff-Werner
Department of Urology, Faculty of Medicine, University of Rostock, Ernst-Heydemann-Str. 6, D-18057 Rostock, Germany.

BACKGROUND Prostate-specific antigen (PSA) is the single most important tumor marker in early detection and monitoring of prostate cancer (CaP). However, routine analysis of serum PSA concentrations does not allow differentiation between CaP and prostatic diseases. The aim of the present study was to evaluate the usefulness of the serum-to-urinary PSA ratio in a clinical setting. METHODS In a retrospective clinical study, we determined serum and urine PSA concentrations in 48 patients with benign prostatic hyperplasia (BPH) and 57 patients with histologically confirmed CaP. RESULTS The serum-to-urinary PSA ratio is able to discriminate BPH from CaP. CONCLUSIONS Determination of the serum-to-urinary PSA ratio enhances the specificity of PSA in screening for CaP and monitoring of patients with CaP under androgen deprivation therapy.

UI MeSH Term Description Entries
D008297 Male Males
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011470 Prostatic Hyperplasia Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both. Adenoma, Prostatic,Benign Prostatic Hyperplasia,Prostatic Adenoma,Prostatic Hyperplasia, Benign,Prostatic Hypertrophy,Prostatic Hypertrophy, Benign,Adenomas, Prostatic,Benign Prostatic Hyperplasias,Benign Prostatic Hypertrophy,Hyperplasia, Benign Prostatic,Hyperplasia, Prostatic,Hyperplasias, Benign Prostatic,Hypertrophies, Prostatic,Hypertrophy, Benign Prostatic,Hypertrophy, Prostatic,Prostatic Adenomas,Prostatic Hyperplasias, Benign,Prostatic Hypertrophies
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D017430 Prostate-Specific Antigen A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer. Kallikrein hK3,gamma-Seminoprotein,hK3 Kallikrein,Prostate Specific Antigen,Semenogelase,Seminin,Kallikrein, hK3,gamma Seminoprotein

Related Publications

M Hillenbrand, and M Bastian, and M Steiner, and C Zingler, and M Müller, and J M Wolff, and H Seiter, and P Schuff-Werner
Serum-to-urinary prostate-specific antigen ratio: a potential means of distinguishing benign prostatic hyperplasia from prostate cancer.
January 1996, European urology,
M Hillenbrand, and M Bastian, and M Steiner, and C Zingler, and M Müller, and J M Wolff, and H Seiter, and P Schuff-Werner
Free-to-total prostate-specific antigen serum concentrations in patients with prostate cancer and benign prostatic hyperplasia.
September 1996, British journal of urology,
M Hillenbrand, and M Bastian, and M Steiner, and C Zingler, and M Müller, and J M Wolff, and H Seiter, and P Schuff-Werner
Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia.
December 1997, The Journal of urology,
M Hillenbrand, and M Bastian, and M Steiner, and C Zingler, and M Müller, and J M Wolff, and H Seiter, and P Schuff-Werner
[Prostate-specific antigen in patients with benign prostatic hyperplasia].
September 1994, Rozhledy v chirurgii : mesicnik Ceskoslovenske chirurgicke spolecnosti,
M Hillenbrand, and M Bastian, and M Steiner, and C Zingler, and M Müller, and J M Wolff, and H Seiter, and P Schuff-Werner
[Prostate-specific antigen in cancer and benign prostatic hyperplasia].
September 1997, Biulleten' eksperimental'noi biologii i meditsiny,
M Hillenbrand, and M Bastian, and M Steiner, and C Zingler, and M Müller, and J M Wolff, and H Seiter, and P Schuff-Werner
Serum prostate specific antigen levels in men with benign prostatic hyperplasia and cancer of prostate.
January 2004, East African medical journal,
M Hillenbrand, and M Bastian, and M Steiner, and C Zingler, and M Müller, and J M Wolff, and H Seiter, and P Schuff-Werner
Autoantibodies to prostate specific antigen in patients with benign prostatic hyperplasia.
September 1995, The Journal of urology,
M Hillenbrand, and M Bastian, and M Steiner, and C Zingler, and M Müller, and J M Wolff, and H Seiter, and P Schuff-Werner
[Prostate-specific antigen in serum and prostate epithelium in benign prostatic hyperplasia].
February 2007, Georgian medical news,
M Hillenbrand, and M Bastian, and M Steiner, and C Zingler, and M Müller, and J M Wolff, and H Seiter, and P Schuff-Werner
Urinary prostate-specific antigen: predictor of benign prostatic hyperplasia progression?
April 2013, The Canadian journal of urology,
M Hillenbrand, and M Bastian, and M Steiner, and C Zingler, and M Müller, and J M Wolff, and H Seiter, and P Schuff-Werner
Benign prostatic hyperplasia and prostate-specific antigen.
May 2015, Vojnosanitetski pregled,
Copied contents to your clipboard!